Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 102

Sort by

Sort Order Select

Journal Articles

Molecular Treatment Stratification for Newly Diagnosed High-Risk Myeloma, Including Plasma Cell Leukemia - Feasibility Results of the Ukmra Optimum: MUK9 Trial (NCT03188172)

Matthew Jenner, MBBS, MRCP, FRCPath, Amy L Sherborne, PhD, Andrew Hall, Vallari Shah, Katrina Walker, Sidra Ellis, Kim Sharp, Amy Price, James Croft, MBBS, BSc, Graham Jackson, MA, MB BS, FRCP, FRCPath, MD, Louise Flanagan, PhD, Mark T Drayson, MB ChB, PhD FRCPath, Ruth M De Tute, BSc,MSc, Roger G. Owen, MD, Guy Pratt, Gordon Cook, Sarah R Brown, PhD MSc, BSc, Martin F. Kaiser

Blood (2019) 134 (Supplement_1): 3162.

https://doi.org/10.1182/blood-2019-123547

Published: 2019

Journal Articles

Long Term Nomacopan Administration Results in Complete Transfusion Independence in Previously Transfusion-Dependent PNH Patients

Austin Kulasekararaj, MBBS MDMRCP FRCPath, Wynne Weston-Davies, Tadeusz Robak, MD, Miles Nunn, PhD, Agnieszka Piekarska, MD, Anna Szmigielska-Kaplon, MD, Anita Hill, MD PhD

Blood (2019) 134 (Supplement_1): 4797.

https://doi.org/10.1182/blood-2019-125263

Published: 2019

Journal Articles

CG-806, a First-in-Class Pan-FLT3/Pan-BTK Inhibitor, Exhibits Broad Signaling Inhibition in Chronic Lymphocytic Leukemia Cells

Ekaterina Kim, MS, Hongying Zhang, MD PhD, Mariela Sivina, Alicia Vaca, PhD, Philip A. Thompson, MBBS, Nitin Jain, MD, Alessandra Ferrajoli, MD, Zeev E. Estrov, MD, Michael J Keating, MBBS, William G. Wierda, MD PhD, William G Rice, PhD, Michael Andreeff, MD PhD, Jan A. Burger, MD PhD

Blood (2019) 134 (Supplement_1): 3051.

https://doi.org/10.1182/blood-2019-124473

Published: 2019

Journal Articles

Superiority of IFN Versus HU Using a Novel Biomarker-Based Tool for Assessment of Disease Burden in MPNs

Vibe Skov, PhD, Marc JB Dam, Rasmus K Pedersen, Morten Andersen, PhD, Trine Alma Knudsen, MD, Zamra Sajid, Lasse Kjær, PhD, Christina Ellervik, MD PhD, Hans Hasselbalch, MD, Johnny T Ottesen, PhD

Blood (2019) 134 (Supplement_1): 2972.

https://doi.org/10.1182/blood-2019-126819

Published: 2019

Journal Articles

Significantly Upregulated Thrombo-Inflammatory Genes Are Normoregulated or Significantly Downregulated during Treatment with Interferon-Alpha2 in Patients with Philadelphia-Negative Chronic Myeloproliferative Neoplasms

Vibe Skov, PhD, Caroline Riley, PhD, Mads Thomassen, PhD, Lasse Kjær, PhD, Thomas Stauffer Larsen, MD PhD, Torben A Kruse, Hans Hasselbalch, MD

Blood (2019) 134 (Supplement_1): 2978.

https://doi.org/10.1182/blood-2019-131698

Published: 2019

Journal Articles

Targeted Protein Degradation of BTK As a Unique Therapeutic Approach for B Cell Malignancies

Blood (2019) 134 (Supplement_1): 3805.

https://doi.org/10.1182/blood-2019-129262

Published: 2019

Journal Articles

Long Term Responses to Venetoclax and Ibrutinib in Mantle Cell Lymphoma Are Associated with Immunological Recovery and Prognostic Changes in Inflammatory Biomarkers

Joanne Davis, PhD, Sasanka M Handunnetti, MBBS, Chia Sharpe, Gillian Turner, Mary Ann Anderson, MBBS, PhD FRACP, FRCPA, Andrew W. Roberts, MBBS, PhD, John F. Seymour, MBBS, PhD FRACP, Constantine S. Tam, MBBS, MD, David Ritchie, MD PhD, Rachel Koldej

Blood (2019) 134 (Supplement_1): 2791.

https://doi.org/10.1182/blood-2019-122974

Published: 2019

Journal Articles

Influence of Age on Treatment with Thrombopoietin Receptor Agonists in Patients with Immune Thrombocytopenia; A Retrospective Multicenter Study

Blood (2019) 134 (Supplement_1): 2361.

https://doi.org/10.1182/blood-2019-122237

Published: 2019

Journal Articles

Sex Differences in Risk Factors, Clinical Presentation, Treatment and Outcomes of Patients Presenting with Acute Pulmonary Embolism

Rachel P Rosovsky, MDMPH, Islam Y Elgendy, MD, Suzanne C Cannegieter, MD PhD, Menno V Huisman, MD PhD, David Jimenez, MD PhD, Jorge del Toro, MD, Vladimir Rosa, MD PhD, Carmen Fernández-Capitán, MD PhD, Alessandra Bura-Riviere, MD PhD, Manuel Monreal, MD PhD

Blood (2019) 134 (Supplement_1): 2429.

https://doi.org/10.1182/blood-2019-131090

Published: 2019

Journal Articles

Chronic Myeloid Leukemia Italian Multicenter Observational Study (CML-IT-MOS): Clinical Characteristics of Chronic Myeloid Leukemia (CML) Patients Treated in Real-Life between 2012 and 2016 in 66 Italian Hematology Centers of the Gimema Study Group

Blood (2018) 132 (Supplement 1): 45.

https://doi.org/10.1182/blood-2018-99-116648

Published: 2018

Journal Articles

Combining Imatinib-Following-Nilotinib Treatment in First Line Therapy for Chronic Phase Chronic Myeloid Leukemia. Update from the PhilosoPhi34 Study at 24 Months of Follow-up

Blood (2018) 132 (Supplement 1): 5435.

https://doi.org/10.1182/blood-2018-99-113496

Published: 2018

Journal Articles

Management of Cytopenias in CTLA4 Haploinsufficiency Using Abatacept and Sirolimus

Gulbu Uzel, MD, Djuro Karanovic, MD, Hua Su, PhD, Amy Rump, Anahita Agharahimi, Steven M. Holland, MD, V. Koneti Rao, MD FRCPA

Blood (2018) 132 (Supplement 1): 2409.

https://doi.org/10.1182/blood-2018-99-120185

Published: 2018

Journal Articles

Long-Term Efficacy and Safety of Ropeginterferon Alfa-2b in Patients with Polycythemia Vera — Final Phase I/II Peginvera Study Results

Blood (2018) 132 (Supplement 1): 3030.

https://doi.org/10.1182/blood-2018-99-118584

Published: 2018

Journal Articles

Novel Therapeutic Targeting of UHRF1 Restores 5'-Azacytidine Response in Resistant Acute Myeloid Leukemia

Anup Kumar Singh, MS, PhD, Xiaochun Yu, MD PhD

Blood (2018) 132 (Supplement 1): 1356.

https://doi.org/10.1182/blood-2018-99-115735

Published: 2018

Journal Articles

Results from the 208-Week (4-Year) Follow-up of RESPONSE Trial, a Phase 3 Study Comparing Ruxolitinib (Rux) with Best Available Therapy (BAT) for the Treatment of Polycythemia Vera (PV)

Blood (2017) 130 (Supplement 1): 322.

https://doi.org/10.1182/blood.V130.Suppl_1.322.322

Published: 2017

Journal Articles

Tourmaline US-MM6, an Open-Label, Single-Arm, Multicenter Study Evaluating the Effectiveness and Safety of Ixazomib in Combination with Lenalidomide and Dexamethasone (IRd) in Patients (pts) with Newly Diagnosed Multiple Myeloma (NDMM) Switching from a Bortezomib-Based Triplet Induction Regimen

Robert M Rifkin, MD, Ralph V. Boccia, MD, Suman Kambhampati, MD, Joshua R Richter, MD, Saad Z Usmani, MD, Jack Aiello, EE, MS, BS, Brittany Sickler, BA, BS, Magdalena Schoeneich, MBA, MS, Bingxia Wang, PhD, Susan Zelt, PhD, Presley Whidden, MS, Lawrence E Dollar, PharmD, MS, Liviu Niculescu, MD, Stephen J Noga, MD

Blood (2017) 130 (Supplement 1): 5407.

https://doi.org/10.1182/blood.V130.Suppl_1.5407.5407

Published: 2017

Journal Articles

High IGF1R Expression Is Associated with Worse Prognosis in CLL and Impacts Response to PI3K-δ Inhibitor Treatment

Annika Scheffold, Billy Michael Chelliah Jebaraj, PhD, Johannes Bloehdorn, MD, Eugen Tausch, MD, Jasmin Bahlo, PhD, Sandra Robrecht, PhD, Kirsten Fischer, MD, Michael Hallek, MD, Hartmut Döhner, MD, Daniel Mertens, PhD, Stephan Stilgenbauer, MD PhD

Blood (2017) 130 (Supplement 1): 390.

https://doi.org/10.1182/blood.V130.Suppl_1.390.390

Published: 2017

Journal Articles

Efficacy and Safety of Long-Term Ixazomib Maintenance Therapy in Patients (Pts) with Newly Diagnosed Multiple Myeloma (NDMM) Not Undergoing Transplant: An Integrated Analysis of Four Phase 1/2 Studies

Meletios A. Dimopoulos, Jacob Laubach, MD, Maria Asuncion Echeveste Gutierrez, Norbert Grząśko, Craig C Hofmeister, MDMPH, Jesus F. San Miguel, MD, Shaji K Kumar, MD, Vickie Lu, PhD, Zhaoyang Teng, PhD, Guohui Liu, PhD, Catriona Byrne, RN, Deborah Berg, RN, MSN, Richard Labotka, MD MS, Helgi van de Velde, MD PhD, Paul G Richardson, MD

Blood (2017) 130 (Supplement 1): 902.

https://doi.org/10.1182/blood.V130.Suppl_1.902.902

Published: 2017

Journal Articles

Dissecting the Role of Individual Bcl-2 Members in Response and Resistance to Ibrutinib or Venetoclax in CLL

Fabio Brocco, Hanneke ter Burg, Stacey Fernandes, Constantine S. Tam, MBBS, MD FRACP, FRCPA, Francesco Forconi, MD DM, PhD FRCPath, Rachel M Guerra, Gregory Bird, Loren D Walensky, Jennifer R. Brown, MD PhD, Arnon P Kater, Eric Eldering

Blood (2017) 130 (Supplement 1): 262.

https://doi.org/10.1182/blood.V130.Suppl_1.262.262

Published: 2017

Journal Articles

Effect of Continuous Lenalidomide Treatment on Copy Number Alteration and Cytogenetic Abnormalities in Multiple Myeloma Cells

Paola Storti, PhD, Marina Bolzoni, PhD, Francesca Novara, PhD, Giannalisa Todaro, PhD, Valentina Marchica, Federica Costa, PhD, Tania Maldacena, PhD, Laura Notarfranchi, MD, Fabrizio Accardi, MD, Orsetta Zuffardi, PhD, Franco Aversa, MD, Nicola Giuliani, MD PhD, Gabriella Sammarelli, PhD

Blood (2017) 130 (Supplement 1): 3039.

https://doi.org/10.1182/blood.V130.Suppl_1.3039.3039

Published: 2017

NARROW

Molecular Treatment Stratification for Newly Diagnosed High-Risk Myeloma, Including Plasma Cell Leukemia - Feasibility Results of the Ukmra Optimum: MUK9 Trial (NCT03188172)

Long Term Nomacopan Administration Results in Complete Transfusion Independence in Previously Transfusion-Dependent PNH Patients

CG-806, a First-in-Class Pan-FLT3/Pan-BTK Inhibitor, Exhibits Broad Signaling Inhibition in Chronic Lymphocytic Leukemia Cells

Superiority of IFN Versus HU Using a Novel Biomarker-Based Tool for Assessment of Disease Burden in MPNs

Significantly Upregulated Thrombo-Inflammatory Genes Are Normoregulated or Significantly Downregulated during Treatment with Interferon-Alpha2 in Patients with Philadelphia-Negative Chronic Myeloproliferative Neoplasms

Targeted Protein Degradation of BTK As a Unique Therapeutic Approach for B Cell Malignancies

Long Term Responses to Venetoclax and Ibrutinib in Mantle Cell Lymphoma Are Associated with Immunological Recovery and Prognostic Changes in Inflammatory Biomarkers

Influence of Age on Treatment with Thrombopoietin Receptor Agonists in Patients with Immune Thrombocytopenia; A Retrospective Multicenter Study

Sex Differences in Risk Factors, Clinical Presentation, Treatment and Outcomes of Patients Presenting with Acute Pulmonary Embolism

Chronic Myeloid Leukemia Italian Multicenter Observational Study (CML-IT-MOS): Clinical Characteristics of Chronic Myeloid Leukemia (CML) Patients Treated in Real-Life between 2012 and 2016 in 66 Italian Hematology Centers of the Gimema Study Group

Combining Imatinib-Following-Nilotinib Treatment in First Line Therapy for Chronic Phase Chronic Myeloid Leukemia. Update from the PhilosoPhi34 Study at 24 Months of Follow-up

Management of Cytopenias in CTLA4 Haploinsufficiency Using Abatacept and Sirolimus

Long-Term Efficacy and Safety of Ropeginterferon Alfa-2b in Patients with Polycythemia Vera — Final Phase I/II Peginvera Study Results

Novel Therapeutic Targeting of UHRF1 Restores 5'-Azacytidine Response in Resistant Acute Myeloid Leukemia

Results from the 208-Week (4-Year) Follow-up of RESPONSE Trial, a Phase 3 Study Comparing Ruxolitinib (Rux) with Best Available Therapy (BAT) for the Treatment of Polycythemia Vera (PV)

Tourmaline US-MM6, an Open-Label, Single-Arm, Multicenter Study Evaluating the Effectiveness and Safety of Ixazomib in Combination with Lenalidomide and Dexamethasone (IRd) in Patients (pts) with Newly Diagnosed Multiple Myeloma (NDMM) Switching from a Bortezomib-Based Triplet Induction Regimen

High IGF1R Expression Is Associated with Worse Prognosis in CLL and Impacts Response to PI3K-δ Inhibitor Treatment

Efficacy and Safety of Long-Term Ixazomib Maintenance Therapy in Patients (Pts) with Newly Diagnosed Multiple Myeloma (NDMM) Not Undergoing Transplant: An Integrated Analysis of Four Phase 1/2 Studies

Dissecting the Role of Individual Bcl-2 Members in Response and Resistance to Ibrutinib or Venetoclax in CLL

Effect of Continuous Lenalidomide Treatment on Copy Number Alteration and Cytogenetic Abnormalities in Multiple Myeloma Cells

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only